AT-7519 is an orally bioavailable small molecule CDK inhibitor with potential antineoplastic activity. AT7519M selectively binds to and inhibits cyclin dependent kinases (CDKs), which may result in cell cycle arrest, induction of apoptosis, and inhibition of tumor cell proliferation. CDKs are serine/theronine kinases involved in regulation of the cell cycle and may be overexpressed in some types of cancer cells.
AT7519 HCl is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM in cell-free assays. It is less potent to CDK3 and little active to CDK7. Phase 2.
Related Prodcuts:
Doxorubicin HCl; Epirubicin; Epirubicin HCl; Idarubicin HCl; Pirarubicin; Amrubicin; Amrubicin HCL; AMG 900; YK-4-279; Belinostat; Resminostat; Resminostat hydrochloride; Mizoribine; Daunorubicin hydrochloride